BioFocus, a provider of integrated gene-to-clinical candidate drug discovery based around bioinformatics, has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. According to BioFocus, the total value of the collaboration between the two companies has now reached €2.5m.
Under the terms of the extended collaboration agreement, BioFocus will provide medicinal chemistry and biology services, with an additional option for ADME services, for an undisclosed Chiesi therapeutic program.
'BioFocus has a high return business rate with clients, and we are pleased that Chiesi has chosen to extend this successful collaboration,' said Onno van de Stolpe, CEO of Galapagos. 'The quality of the science at BioFocus enables it to sustain its position as a premier provider in drug discovery services.'
'The medicinal chemistry and biology work performed by BioFocus has so far helped us to accelerate progress on our therapeutic programs. We look forward to working with BioFocus to move these programs forward toward the clinic,' said Dr Paolo Chiesi, R&D director and vice-president of Chiesi Farmaceutici.
